In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn't yet been approved ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmac ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...